Mount Sinai, Johnson & Johnson Partner to Study Targeted Radioembolization for Brain Tumors
KEY TAKEAWAYS
- Mount Sinai and Cerenovus, a Johnson & Johnson company, entered a collaborative research agreement to evaluate an investigational liquid radioembolic approach for the treatment of people with brain tumors.
- The strategy combines iodine-131 with TRUFILL n-BCA to occlude tumor-feeding vessels while concentrating radiation within the targeted vasculature.
- Initial work will focus on meningiomas and will begin with vascular modeling, imaging, and preclinical assessment before any future clinical study.
The Icahn School of Medicine at Mount Sinai, New York City, NY, entered a collaborative research agreement with Cerenovus (Irvine, CA), a Johnson & Johnson (New Brunswick, NJ) company, to evaluate an investigational liquid radioembolic agent for brain tumors.
The approach combines iodine-131 with TRUFILL n-BCA, an embolic material, with the goal of both reducing blood flow to a tumor and delivering localized radiation through its feeding vessels. The initial research program will focus on meningiomas.
Rather than proceeding directly to clinical testing, investigators plan to first optimize the formulation and delivery strategy and assess how the agent distributes within tumor-associated vasculature. The program will use patient-derived 3-dimensional printed vascular models together with advanced imaging, followed by preclinical evaluation.
Research Program Details
- The investigational strategy is designed to pair embolization with localized radiation delivery through tumor-feeding vessels.
- Meningiomas will serve as the first tumor type evaluated.
- Early work will assess technical feasibility, agent localization, and delivery characteristics in controlled models.
- The collaboration is intended to generate data that could support future clinical studies if the approach demonstrates sufficient safety and feasibility.
Source
Mount Sinai Health System. Mount Sinai announces collaborative research agreement to evaluate novel liquid radioembolic agent for brain tumors. Published September 28, 2026. Accessed September 29, 2026. https://www.mountsinai.org/about/newsroom/2026/mount-sinai-announces-collaborative-research-agreement-to-evaluate-novel-liquid-radioembolic-agent-for-brain-tumors